Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Inclusion Criteria:

• Diagnosis with metastatic renal cell carcinoma
• Prescription/administration of one of the IV or oral agents examined in the study

Exclusion Criteria:

• Patients with other primary cancer diagnosis before RCC diagnosis
• Patients with pregnancy or HIV/AIDS